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Brain metastases are a common complication of non-small-cell lung cancer (NSCLC). The role of chemotherapy in the treatment of
brain metastases has not been clearly defined. Emerging case reports of patients with recurrent NSCLC treated as part of the
Expanded Access Programme reveal that gefitinib (‘Iressa’, ZD1839) has clinical activity in some patients with brain metastases. Here,
we describe a number of case studies documenting the response of patients with brain metastases to treatment with gefitinib. Many
of these patients had quality-of-life benefits with improvement of neurological and systemic symptoms; some had a partial response
of their brain metastases and even complete responses have been seen in a few patients. One case report also describes a durable
long-term response with concurrent treatment with gefitinib and radiotherapy. Such results call for larger trials designed to evaluate
and define the role of gefitinib in the treatment of brain metastases in NSCLC patients, either as a single agent or in combination with
radiation therapy.
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Brain metastases are a common complication for patients with
non-small-cell lung cancer (NSCLC) and a significant cause of
morbidity and mortality. Radiotherapy remains the mainstay of
treatment for brain metastases; however, patients treated with
whole-brain radiation still have a poor prognosis with a median
survival of only 3–4 months (Rodrigus et al, 2001). The role of
chemotherapy in the treatment of patients with brain metastases
has not been clearly defined. Many of these tumours are relatively
resistant to chemotherapy and, traditionally, it has been assumed
that the blood–brain barrier prevented chemotherapeutic agents
from entering the central nervous system (CNS). However, the
blood–brain barrier is disrupted in malignant brain tumours and
recent evidence suggests that the chemosensitivity of the primary
tumour is the major determinant of the response to systemic
treatment of brain metastases, rather than the ability of the agent
to penetrate an intact blood–brain barrier.
Gefitinib (‘Iressa’, ZD1839) is an orally active, epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor that blocks signal
transduction pathways implicated in the proliferation and survival
of cancer cells. High levels of EGFR are frequently found in
malignant primary brain tumours (Ekstrand et al, 1992) and in
tumours that often metastasise to the CNS, such as NSCLC and
breast cancer (Wikstrand et al, 1995). Large Phase II studies have
recently shown that gefitinib has clinical activity in advanced
NSCLC and is well tolerated (Fukuoka et al, 2003; Kris et al, 2003).
A preclinical study in mice showed that gefitinib retains
therapeutic activity on intracranial tumours despite the blood–
brain barrier (Heimberger et al, 2002). Oral administration of
gefitinib at 50 or 100mgkg
 1day
 1 for 3 weeks in athymic mice
with established intracerebral A431 human epidermoid carcinoma
expressing EGFR increased median survival by 88% (P¼0.009)
and 105% (Po0.001), respectively. The preliminary results of a
Phase II study also show modest activity of gefitinib in patients
with recurrent glioblastoma (Peery et al, 2003).
Recently, a number of case reports of patients with recurrent
NSCLC treated with gefitinib as part of the Expanded Access
Programme (EAP) have described promising activity in patients
with brain metastases. Here, we accumulate these results and
discuss the possible implications and future directions.
GEFITINIB IN PATIENTS WITH BRAIN METASTASES:
RESULTS FROM THE EAP
The case reports of patients with brain metastases secondary to
NSCLC treated with gefitinib as part of the compassionate-use
programme have recently been reported as published case studies
(Cappuzzo et al, 2003a, b; Fujiwara et al, 2003; Knuti et al, 2003;
Villano et al, 2003), at the World Conference on Lung Cancer 2003
(Chiu et al, 2003; Pino et al, 2003), at the American Society of
Clinical Oncology 2003 conference (Ceresoli et al, 2003) and at the
‘Iressa’ Clinical Experience (ICE) meeting (Awada, ICE abs;
Cappuzzo [a & b], ICE abs; Dieriks, ICE abs; Stein, ICE abs; de
la Cruz [a & b], ICE abs; Maione, ICE abs; Martı ´nez, ICE abs; Diaz-
Canto ´n, ICE abs; van der Kamp, ICE abs; van Zandwijk [b], ICE
abs; Petruzelka [a], ICE abs; Aze ´mar, ICE abs; Roggero, ICE abs;
Kowalski, ICE abs; Martı ´n-Algarra, ICE abs; Pavlakis, ICE abs).
(See appendix for ICE abstracts). Together, these case reports
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results of published case series are shown in Table 1.
Most notable are the cases with a complete remission of brain
metastases. In the largest case series that included 27 patients who
had asymptomatic or symptomatic brain metastases, two of 20
evaluable patients had a response in the brain, with complete
remission in one patient (Ceresoli et al, 2003). In another case
series described in two separate publications by Cappuzzo et al,
eight patients with NSCLC and brain metastases were treated with
gefitinib (Cappuzzo et al, 2003a, b; [a & b] ICE abs). One patient
had a complete response and seven had partial responses in the
brain, all within 3 months of treatment. The complete response in
the brain was observed 6 weeks after treatment with gefitinib
started in a patient who had completed whole-brain radiotherapy 3
months prior to the beginning of gefitinib (Figure 1). All eight
patients experienced improvements in neurological and systemic
symptoms.
Fujiwara et al (2003) described the case report of a patient who
had achieved a complete response in the brain following treatment
with gefitinib. This particular patient was diagnosed in July 1999
with stage IV adenocarcinoma of the left lung. In March 2001, after
treatment with three different chemotherapy regimens, asympto-
matic brain metastases were detected and subsequently treated
with whole-brain radiotherapy. However, by October 2001 the
patient’s condition had deteriorated, with progressive brain
metastases, and the patient was readmitted to hospital. Treatment
with gefitinib started in November 2001 after which computed
tomography scans showed that brain metastases had disappeared
and that there was a marked regression of the lung tumour. The
patient was then discharged in December 2001 and was able to
resume full-time work for nearly 8 months. Two other published
case reports also describe patients whose brain metastases
responded to treatment (Knuti et al, 2003; Villano et al, 2003).
In all three of these cases, patients had worsening neurological
symptoms and deteriorating performance status before treatment
with gefitinib. Following treatment, a significant clinical improve-
ment was seen in all three patients: brain metastases disappeared
in the patient already described and the sizes of the other two
patients’ lesions decreased. Quality of life was improved in all three
patients.
One patient described at the ICE meeting showed good tolerance
of concurrent gefitinib and radiotherapy (van Zandwijk [b], ICE
abs, personal communication). In this case study, a 55-year-old
male exsmoker with stage IV NSCLC and multiple pulmonary
(lymphangitic) metastases developed multiple brain metastases
(approximately 20 small lesions) after receiving treatment with
gefitinib for 41 year (Figure 2). Radiotherapy to the brain
(10 3Gy) and continued treatment with gefitinib resulted in
disease stabilisation and symptom improvement and the patient
was able to return to work. Delayed imaging 9 months later showed
almost complete resolution of the brain metastases (Figure 3).
Thus, although gefitinib did not prevent the development of brain
metastases, concurrent treatment with radiotherapy and gefitinib
resulted in a durable clinical response.
In total, 25 case reports of gefitinib use in patients with brain
metastases and NSCLC were described at the ICE meeting
(including the eight patients described by Cappuzzo et al) (Awada,
ICE abs; Cappuzzo [a & b], ICE abs; Dieriks, ICE abs; Stein, ICE
abs; de la Cruz [a & b], ICE abs; Maione, ICE abs; Martı ´nez, ICE
abs; Diaz-Canto ´n, ICE abs; van der Kamp, ICE abs; van Zandwijk
[b], ICE abs; Petruzelka [a], ICE abs; Aze ´mar, ICE abs; Roggero,
Table 1 Published case series of patients with brain metastases and non-small-cell lung cancer treated with gefitinib as part of the Expanded Access
Programme
Patients Previous treatment Results
Pino et al (2003) n¼63, of whom 11 patients One prior chemotherapy regimen: 18 Of 11 patients with brain metastases,
had brain metastases Two prior chemotherapy regimens: 42 two had a response in the brain
Chiu et al (2003) n¼57, of whom 16 had brain metastases One prior chemotherapy regimen: 1 Of 16 patients with brain metastases,
X2 prior chemotherapy regimens: 15 two had a partial response
Ceresoli et al (2003) n¼27, all with brain metastases Platinum-based chemotherapy: 20 Two patients had a response in the brain,
Brain radiotherapy: 11 one with complete remission
(both had brain radiotherapy 43 months
before starting gefitinib)
Cappuzzo et al (2003a) n¼4, all with brain metastases X2 prior chemotherapy regimens: 4
Whole-brain radiotherapy: 3
One patient had a complete response and three
patients had a partial response of brain metastases
Response duration: 3+, 5, 7, 12+ months
Cappuzzo et al (2003b) n¼4, all with brain metastases One prior chemotherapy regimen: 2
X2 prior chemotherapy regimens: 2
All four patients had a partial response of
brain metastases
Whole-brain radiotherapy: 2 Response duration: 6+, 8, 11+, 15 months
Before
R
R
L
L
3 months after
Figure 1 Computed tomography scan before and after treatment with
gefitinib. Reproduced with permission from: Cappuzzo F, Calandri C,
Bartolini S, Crino L (2003b).
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abs). Of these, three patients had a complete response, 10 a partial
response, eight had stable disease and four patients had
progression of their brain metastases. In all of these case reports,
treatment with gefitinib appears to have been well tolerated. Any
reported adverse events are consistent with the adverse-event
profile of gefitinib established in Phase II trials in patients with
advanced NSCLC (Fukuoka et al, 2003; Kris et al, 2003). There was
also no unexpected or cumulative toxicity described for the patient
who received concurrent gefitinib and radiotherapy (van Zandwijk
[b], ICE abs).
DISCUSSION
A number of case reports suggest that gefitinib has clinical activity
against brain metastases of patients with NSCLC. These prelimin-
ary data indicate that patients with brain metastases should not be
excluded from treatment with gefitinib (as they were in some of the
early clinical trials of gefitinib), an opinion also expressed by
Cappuzzo et al (2003b). There is a need for larger trials to follow-
up these positive preliminary findings in the hope of developing a
treatment option for these patients who have a very poor
prognosis. Combination of radiotherapy and gefitinib adminis-
tered either concurrently or sequentially warrants further inves-
tigation.
A consideration for such future studies in patients with brain
metastases is the optimum dose of gefitinib if dexamethasone is
also being administered. Dexamethasone is an inducer of
cytochrome P450 3A isoenzymes, including CYP 3A4, which has
been identified as the isoenzyme primarily involved in the
metabolism of gefitinib. Therefore, coadministration of dexa-
methasone may lead to increased metabolism of gefitinib, with
consequently lower plasma concentrations and potentially reduced
efficacy. In addition, such studies would need to use standardised
patient staging to identify and monitor asymptomatic as well as
symptomatic brain metastases.
A number of preclinical studies support the combined use of
radiotherapy and gefitinib as a strategy for cancer treatment
(Bianco et al, 2002; Huang et al, 2002; Magne et al, 2002; Williams
et al, 2002; Solomon et al, 2003). Coadministration of gefitinib
potentiated the antitumour effect of radiation on A431 cells
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A 55-year-old male exsmoker with stage IV non-small-cell lung cancer and multiple
pulmonary (lymphagitic) metastases, World Health Organization (WHO) performance status 1
No significant medical history
Treated with cisplatin/gemcitabine for 3 months followed by gemcitabine alone for 4 months
Partial response achieved
Patient came off treatment
Disease recurred, treated with oral paclitaxel → partial response
Disease progressed
Disease stabilisation
Started taking gefitinib 250 mg day
-1
Shortly after start of therapy pleural fluid increased; evacuation and pleurodesis were
needed. After a number of weeks there was a gradual improvement in this condition,
which eventually resolved completely
Slight skin rash at start of therapy
Gradual symptom improvement
Gradual improvement in symptoms
Patient returned to work: WHO performance status 0-1
Development of brain metastases (~20 small lesions)
Chest X-ray revealed stable disease
Radiotherapy to brain metastases (10 x 3 Gy), concomitantly with gefitinib
WHO performance status 1
Good general condition
Patient returned to work
Response is continuing
MAY 2003
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DECEMBER 1999
Figure 2 Case history of a patient with NSCLC and brain metastases taking gefitinib. Data previously presented by: van Zandwijk N. Risk/benefit of
gefitinib (‘Iressa’, ZD1839). Oral presentation at the ICE meeting, Madrid, June 2003. Used with permission.
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Figure 3 Computed tomography scan before and after treatment with
gefitinib and radiotherapy (case history shown in Figure 2). Previously
presented by: van Zandwijk N. Risk/benefit of gefitinib (‘Iressa’, ZD1839).
Oral presentation at the ICE meeting, Madrid, June 2003. Reproduced with
permission.
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levels of EGFR) both in vitro and in vivo (Solomon et al, 2003).
Another preclinical study showed a cooperative antiproliferative
effect when gefitinib was combined with radiation in colon,
ovarian, NSCLC and breast cancer cell lines (Bianco et al, 2002).
Further, the combination of gefitinib and radiation resulted in
long-term tumour growth regressions of established human colon
cancer GEO and lung adenocarcinoma A549 xenografts (Bianco
et al, 2002). Radiotherapy treatment may also disrupt the blood–
brain barrier (van Vulpen et al, 2002) that would allow improved
access of gefitinib to brain tumour tissue.
In summary, a number of case reports suggest activity of
gefitinib against brain metastases secondary to advanced NSCLC.
Larger trials are needed to validate these findings and further
investigate the potential of combined gefitinib and radiotherapy
treatment.
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